“An effective quality oversight strategy is critical to the success of clinical trials. Ensuring compliance and maintaining inspection readiness has become increasingly complex as risk-based approaches for quality management are being adopted, increases in outsourcing have added to the number of stakeholders involved, and quality management systems are being implemented. This results in many challenges to ensure trial integrity by effectively assessing, optimizing and management the quality of clinical vendors and sites.
At ExL’s 6th Clinical Quality Oversight Forum on October 5-7 in Philly, 30 of the industry’s leading experts from small, mid and large sized companies, such as Vertex, Regeneron, UCB, Shire, Pfizer, Merck, Lilly, AbbVie, Alkermes, Teva, Nektar, Alexion and many more, candidly share their experiences on what’s worked and what hasn’t providing practical and applicable take-away strategies to improve your operations.
Featured topics include:
-Identifying Clinical Quality Metrics
-Achieving Inspection Readiness
-Documenting Vendor Oversight
-Implementing Quality Management Systems
-Optimizing Data Quality
-Executing Escalation Plans and Clinical CAPAs
Join your peers at this comprehensive three-day event to learn, engage and network, and leave with the knowledge and connections to ensure GCP compliance. “